APM Stock Overview
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Aptorum Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.48 |
| 52 Week High | US$17.49 |
| 52 Week Low | US$1.35 |
| Beta | 0.55 |
| 1 Month Change | -38.08% |
| 3 Month Change | 204.44% |
| 1 Year Change | 92.96% |
| 3 Year Change | -79.93% |
| 5 Year Change | -96.56% |
| Change since IPO | -96.18% |
Recent News & Updates
Recent updates
Aptorum Group GAAP EPS of -$0.05
Oct 03Is Aptorum Group (NASDAQ:APM) In A Good Position To Deliver On Growth Plans?
Jul 14
Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies
Feb 11Aptorum inks development agreement with Exeltis
May 06We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit
Apr 26Do Institutions Own Aptorum Group Limited (NASDAQ:APM) Shares?
Jan 16Aptorum files for early-stage trial for ALS-4 in Canada
Dec 21Shareholder Returns
| APM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.0% | 0.4% | 1.0% |
| 1Y | 93.0% | 0.9% | 21.9% |
Return vs Industry: APM exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: APM exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| APM volatility | |
|---|---|
| APM Average Weekly Movement | 158.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APM's share price has been volatile over the past 3 months.
Volatility Over Time: APM's weekly volatility has increased from 82% to 158% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 19 | Ian Huen | www.aptorumgroup.com |
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity.
Aptorum Group Limited Fundamentals Summary
| APM fundamental statistics | |
|---|---|
| Market cap | US$29.98m |
| Earnings (TTM) | -US$13.40m |
| Revenue (TTM) | US$1.20m |
25.0x
P/S Ratio-2.2x
P/E RatioIs APM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APM income statement (TTM) | |
|---|---|
| Revenue | US$1.20m |
| Cost of Revenue | US$1.11m |
| Gross Profit | US$87.91k |
| Other Expenses | US$13.49m |
| Earnings | -US$13.40m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.45 |
| Gross Margin | 7.33% |
| Net Profit Margin | -1,116.97% |
| Debt/Equity Ratio | 0% |
How did APM perform over the long term?
See historical performance and comparison